Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A06246 | 32952876 | World J Hepatol | Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. | 2020 | Details |
| A06251 | 32952340 | World J Gastroenterol | Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. | 2020 | Details |
| A06259 | 32951289 | Physiol Rep | Targeted and untargeted metabolomics provide insight into the consequences of glycine-N-methyltransferase deficiency including the novel finding of defective immune function. | 2020 | Details |
| A06260 | 32949785 | Ann Hepatol | Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. | 2020 | Details |
| A06262 | 32947972 | Int J Mol Sci | NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling. | 2020 | Details |
| A06265 | 32947757 | Diabetes Metab Syndr | Nonalcoholic fatty liver disease in males with low testosterone concentrations. | 2020 | Details |
| A06267 | 32946642 | Liver Int | Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. | 2021 | Details |
| A06268 | 32946623 | Hepatol Res | Non-invasive fibrosis markers are associated with mortality risk in both general populations and non-alcoholic fatty liver disease patients. | 2020 | Details |
| A06271 | 32945412 | Mol Med Rep | Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. | 2020 | Details |
| A06277 | 32944984 | J Food Biochem | trans-Chalcone inhibits high-fat diet-induced disturbances in FXR/SREBP-1c/FAS and FXR/Smad-3 pathways in the kidney of rats. | 2020 | Details |
| A06279 | 32943747 | Sci Rep | Difference in lifestyle and metabolic profile of non-alcoholic fatty liver disease with raised alanine amino-transferases between obese and non-overweight subjects. | 2020 | Details |
| A06280 | 32943694 | Sci Rep | A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. | 2020 | Details |
| A06284 | 32942044 | Cell Mol Gastroenterol Hepatol | Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner. | 2020 | Details |
| A06293 | 32938692 | Gut | Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. | 2020 | Details |
| A06294 | 32938556 | Obes Res Clin Pract | Effects of obesity reduction on transient elastography-based parameters in pediatric non-alcoholic fatty liver disease. | 2020 | Details |
| A06295 | 32937687 | Clin Mol Hepatol | Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake. | 2020 | Details |
| A06300 | 32936098 | J R Coll Physicians Edinb | Diagnosis and management of fatty liver. | 2020 | Details |
| A06306 | 32934047 | Clin Med (Lond) | Non-alcoholic fatty liver disease. | 2020 | Details |
| A06310 | 32933184 | Life (Basel) | Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. | 2020 | Details |
| A06317 | 32931760 | Am J Med | The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. | 2020 | Details |
| A06327 | 32927776 | Nutrients | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. | 2020 | Details |
| A06329 | 32926803 | Am J Respir Crit Care Med | Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea. A Randomized Clinical Trial. | 2021 | Details |
| A06331 | 32925501 | Eur J Gastroenterol Hepatol | Obstructive sleep apnea and severity of nonalcoholic fatty liver disease. | 2021 | Details |
| A06335 | 32924526 | Am J Physiol Endocrinol Metab | Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease. | 2020 | Details |
| A06338 | 32923831 | Hepatol Commun | Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. | 2020 | Details |
| A06340 | 32923108 | Am J Cardiovasc Dis | Increased cardiovascular events and mortality in females with NAFLD: a meta-analysis. | 2020 | Details |
| A06343 | 32922061 | Clin Exp Gastroenterol | Changes in Function and Dynamics in Hepatic and Splenic Macrophages in Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A06345 | 32921203 | Expert Rev Proteomics | Serum proteome assessment in nonalcoholic fatty liver disease in children: a preliminary study. | 2020 | Details |
| A06349 | 32920163 | Ann Hepatol | The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. | 2020 | Details |
| A06350 | 32920003 | Life Sci | Hypoxia aggravates non-alcoholic fatty liver disease in presence of high fat choline deficient diet: A pilot study. | 2020 | Details |
| A06353 | 32919087 | Ann Hepatol | Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. | 2020 | Details |
| A06355 | 32918742 | J Pathol | Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression. | 2020 | Details |
| A06356 | 32918399 | Environ Toxicol | Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease. | 2020 | Details |
| A06361 | 32916154 | Metabolism | Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. | 2020 | Details |
| A06363 | 32915852 | PLoS One | Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. | 2020 | Details |
| A06374 | 32908830 | Eur J Case Rep Intern Med | High-Titre ANA Positivity in NAFLD: An Uncommon Presentation of a Common Disease. | 2020 | Details |
| A06375 | 32908189 | Sci Rep | 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) dysregulates hepatic one carbon metabolism during the progression of steatosis to steatohepatitis with fibrosis in mice. | 2020 | Details |
| A06378 | 32906750 | Int J Mol Sci | The Emerging Relevance of AIM2 in Liver Disease. | 2020 | Details |
| A06379 | 32906228 | Clin Mol Hepatol | Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. | 2020 | Details |
| A06380 | 32906165 | Semin Liver Dis | Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. | 2020 | Details |
| A06384 | 32902660 | Abdom Radiol (NY) | Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience. | 2020 | Details |
| A06389 | 32898995 | Medicine (Baltimore) | Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. | 2020 | Details |
| A06390 | 32898706 | Clin Gastroenterol Hepatol | PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06393 | 32897416 | Eur Radiol | Whole-liver histogram and texture analysis on T1 maps improves the risk stratification of advanced fibrosis in NAFLD. | 2020 | Details |
| A06394 | 32896622 | Biochim Biophys Acta Mol Cell Biol Lipids | 12α-Hydroxylated bile acid induces hepatic steatosis with dysbiosis in rats. | 2020 | Details |
| A06396 | 32894439 | Dig Dis Sci | Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare. | 2020 | Details |
| A06399 | 32893039 | Gastroenterol Hepatol | WITHDRAWN: Higher appendicular skeletal muscle mass percentage is an independent protective factor for non-alcoholic steatohepatitis and significant fibrosis in male with NAFLD. | 2020 | Details |
| A06402 | 32892401 | Scand J Immunol | Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). | 2020 | Details |
| A06404 | 32891893 | J Nutr Biochem | Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis. | 2020 | Details |
| A06405 | 32891697 | Biochimie | Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? | 2020 | Details |
| A06415 | 32888418 | Immunity | Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. | 2020 | Details |
| A06427 | 32884438 | Yonago Acta Med | Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A06430 | 32883049 | Cells | A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. | 2020 | Details |
| A06436 | 32882372 | J Hepatol | rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. | 2020 | Details |
| A06438 | 32881371 | Pediatr Obes | Association between obstructive sleep apnea and non-alcoholic fatty liver disease in pediatric patients: a meta-analysis. | 2020 | Details |
| A06439 | 32881244 | Liver Int | A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. | 2021 | Details |
| A06441 | 32880109 | Rev Med Suisse | [NASH: new terminology and what else is new in 2020]. | 2020 | Details |
| A06443 | 32880022 | Clin J Gastroenterol | Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A06446 | 32879216 | Biol Pharm Bull | A Lipid-Based Nanocarrier Containing Active Vitamin D3 Ameliorates NASH in Mice via Direct and Intestine-Mediated Effects on Liver Inflammation. | 2020 | Details |
| A06449 | 32878486 | Expert Rev Gastroenterol Hepatol | Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? | 2020 | Details |
| A06451 | 32877694 | Pharmacol Res | Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action. | 2020 | Details |
| A06453 | 32877569 | Clin Infect Dis | Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. | 2021 | Details |
| A06454 | 32877213 | Am J Physiol Gastrointest Liver Physiol | High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis-associated fibrosis. | 2020 | Details |
| A06457 | 32875543 | J Physiol Biochem | Metabolite profiling of mice under long-term fructose drinking and vitamin D deficiency: increased risks for metabolic syndrome and nonalcoholic fatty liver disease. | 2020 | Details |
| A06459 | 32872474 | Pharmaceuticals (Basel) | Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. | 2020 | Details |
| A06461 | 32872090 | Diagnostics (Basel) | An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. | 2020 | Details |
| A06462 | 32871978 | Medicine (Baltimore) | Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. | 2020 | Details |
| A06474 | 32865911 | Crit Rev Oncog | Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression. | 2020 | Details |
| A06477 | 32864415 | Alzheimers Dement (N Y) | Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. | 2020 | Details |
| A06482 | 32863213 | Redox Biol | Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. | 2020 | Details |
| A06485 | 32861753 | Gastrointest Endosc | Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. | 2020 | Details |
| A06491 | 32856978 | J Med Food | Fisetin Alleviates Hepatic and Adipocyte Fibrosis and Insulin Resistance in Diet-Induced Obese Mice. | 2020 | Details |
| A06501 | 32850903 | Front Med (Lausanne) | Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis. | 2020 | Details |
| A06507 | 32849291 | Front Endocrinol (Lausanne) | Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD. | 2020 | Details |
| A06511 | 32848838 | Front Physiol | Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease. | 2020 | Details |
| A06514 | 32847841 | BMJ Open Diabetes Res Care | Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. | 2020 | Details |
| A06517 | 32845887 | PLoS One | Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. | 2020 | Details |
| A06518 | 32845234 | Med Decis Making | Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. | 2020 | Details |
| A06519 | 32843301 | Sleep Med | Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis. | 2020 | Details |
| A06522 | 32841505 | Liver Int | Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. | 2020 | Details |
| A06524 | 32841307 | PLoS One | Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. | 2020 | Details |
| A06525 | 32841140 | Medicina (B Aires) | [Diagnosis and treatment of non-alcoholic fatty liver disease. Argentine Association for the Study of Liver Diseases, year 2019]. | 2020 | Details |
| A06526 | 32840963 | Liver Int | The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. | 2021 | Details |
| A06527 | 32840311 | J Clin Endocrinol Metab | Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06529 | 32839409 | Biomedicines | Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A06530 | 32839076 | Eur J Intern Med | Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. | 2020 | Details |
| A06537 | 32833053 | Langenbecks Arch Surg | Mechanisms of nonalcoholic fatty liver disease and implications for surgery. | 2020 | Details |
| A06538 | 32833043 | Arch Toxicol | A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats. | 2020 | Details |
| A06542 | 32832491 | Can J Gastroenterol Hepatol | Associations between Phase Angle Values Obtained by Bioelectrical Impedance Analysis and Nonalcoholic Fatty Liver Disease in an Overweight Population. | 2020 | Details |
| A06543 | 32832402 | J Clin Transl Hepatol | NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. | 2020 | Details |
| A06546 | 32831531 | Med Chem Res | Dioxin-like and non-dioxin-like PCBs differentially regulate the hepatic proteome and modify diet-induced nonalcoholic fatty liver disease severity. | 2020 | Details |
| A06548 | 32829997 | J Diabetes Complications | NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. | 2020 | Details |
| A06550 | 32829576 | Ann Lab Med | Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. | 2020 | Details |
| A06551 | 32828745 | Clin Res Hepatol Gastroenterol | Myosteatosis in nonalcoholic fatty liver disease: An exploratory study. | 2020 | Details |
| A06553 | 32827432 | J Clin Endocrinol Metab | Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. | 2020 | Details |
| A06563 | 32824349 | Antioxidants (Basel) | Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A06564 | 32824337 | Int J Mol Sci | History of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06567 | 32823983 | J Clin Med | Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. | 2020 | Details |
| A06570 | 32823613 | Nutrients | Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. | 2020 | Details |
| A06572 | 32822391 | PLoS One | Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. | 2020 | Details |